

SenzaGen secures SEK 0.6 m order from a new European customer in the chemical industry

Lund, February 26, 2021

SenzaGen has received an order with a value of approximately SEK 0.6 million from a new global customer in the chemical industry. The order includes SenzaGen's tests to assess whether chemical substances in products can cause allergic reactions to skin (GARD™skin) or in the respiratory tract (GARD™air). The tests will be carried out in SenzaGen's GLP certified laboratory in Lund.

The customer has its headquarters in Europe and is a leading supplier of specialty chemicals and sustainable technologies. With the combination of GARD™ tests, the customer can identify substances with various allergy-causing effects during both product development and manufacturing for the first time, which contributes to cost savings for the company and safer products to society. At the same time, the customer minimizes the risk during chemical manufacturing by offering a safer work environment.

“The chemical industry has a great need for chemical sensitization testing and is one of our prioritized target markets. With this order we continue to deliver in line with our strategic initiatives. The fact that the customer tests difficult-to-test samples for both skin and respiratory allergies makes this an important reference order”, says Axel Sjöblad, CEO of SenzaGen.

SenzaGen's test platform GARD™ targets companies looking to optimize their *in vitro* testing strategy; increasing the accuracy of their test results while avoiding animal testing. Through its high accuracy, GARD improves the quality of customers' decision-making and contributes to increased product safety in people's everyday lives while reducing the number of animal experiments. SenzaGen is the only company that can offer a non-animal, so called *in vitro* test, for chemical respiratory allergens.

Contacts

Axel Sjöblad, CEO, SenzaGen AB

Email: axel.sjoblad@senzagen.com | Mobile: +46 705-35 93 51

Tina Dackemark Lawesson, VP Marketing & Communications

Email: tina.lawesson@senzagen.com | Mobile: +46 708-20 29 44



About us

SenzaGen is a Swedish biotech company that provides state-of-the-art non-animal tests for assessing a substance's allergenicity. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. With excellent predictivity, GARD® meets needs in several industries and helps companies develop, produce and deliver safer, ethical and more sustainable products. GARD® tests are performed in SenzaGen's GLP-approved lab and by select partners in Europe and the US. SenzaGen has its headquarters in Lund, Sweden and a subsidiary in the US. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company's Certified Adviser.

Attachments

[SenzaGen secures SEK 0.6 m order from a new European customer in the chemical industry](#)